PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
In rat models, H. europaeum significantly shortened bleeding time and accelerated wound healing (healing in 12 days with daily treatment) [PMID:36859573]
Mother tincture of H. europaeum exhibited highly effective results against Bacillus subtilis in all concentrations [PMID:23716878]
A whole-plant butanol fraction (WBFHE) showed anti-inflammatory activity on ROS (IC50 14.7 ± 2.5), though other fractions and the general extract showed no activity [PMID:32076387]
No anticancer activities were exhibited by the extract or fractions of the whole plant [PMID:32076387]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 36859573 (2023) — Preliminary evaluation of haemostatic and wound healing potential of Heliotropium europaeum. · Archives of dermatological research
- 2.PMID: 33525719 (2021) — Comparative Risk Assessment of Three Native Heliotropium Species in Israel. · Molecules (Basel, Switzerland)
- 3.PMID: 35610518 (2022) — Bioassay-directed analysis-based identification of relevant pyrrolizidine alkaloids. · Archives of toxicology
- 4.PMID: 18814656 (2008) — Chemical stress induced by heliotrope (Heliotropium europaeum L.) allelochemicals and increased activity of antioxidant enzymes. · Pakistan journal of biological sciences : PJBS
- 5.PMID: 32076387 (2020) — In Vitro Anti-Inflammatory, Anticancer (MCF-7, 3T3, and HeLa Cell Lines), and Brine Shrimp Lethality Assay and FTIR Analysis of the Extract and Fractions of the Whole Plant of Heliotropium europaeum.